PBM
Psyence Biomedical Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$6.63
+4.83%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.32
From 52W high−79.17%
Volume133112.00
Market cap$25.27M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.32
From 52W high
−79.17%
Volume
133112.00
Market cap
$25.27M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.6x
P/E (TTM)
—
RSI (14)
80.0
MomentumView details →
1D Return
+4.83%
YTD Return
+33.47%
SummaryUpdated Mar 1, 2026
Psyence Biomedical Ltd. (NASDAQ:PBM) is a Canadian biotechnology company founded in 2020 and publicly traded since December 2021. The company specializes in developing botanical psilocybin-based psychedelic medicines for treating mental health conditions, particularly in palliative care settings. Based in Toronto, Canada, Psyence operates as a subsidiary of Psyence Group Inc. and represents one of the emerging players in the nascent psychedelic medicine industry, focusing on naturally-sourced psilocybin rather than synthetic alternatives.
Similar companies
Latest newsMore news →
Psyence Biomedical Ltd. announced the formation of Texas Ibogaine Research Corporation, a Texas-based U.S. vehicle to coordinate its ibogaine development activities including supply, regulatory engagement and potential clinical development.6d agoPsyence Labs Ltd. disclosed a 30.1% stake in Psyence Biomedical Ltd. via a 13D/G filing.110d ago